New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2013
09:16 EDTCTICCell Therapeutics has opportunity in MF, says Roth Capital
After attending Cell Therapeutics' Analyst Day, Roth Capital believes the company's pacritinib drug has a material opportunity to become a treatment for myelofibrosis, or MF, given the drug's differentiated profile of having a minimal effect on platelets. The firm maintains a $4 price target and Buy rating on the stock.
News For CTIC From The Last 14 Days
Check below for free stories on CTIC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 19, 2014
20:10 EDTCTICCell Therapeutics in pact with DSM Fine Chemicals Austria
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use